ACTA FAC MED NAISS 2007; 24 (4): 183-188 |
Review article
THE ROLE OF PREGNANCY-ASSOCIATED PLASMA PROTEIN-A (PAPP-A) IN THE IDENTIFICATION OF CORONARY ARTERY DISEASE ACTIVITY
Ivana
Petrovic1
Marina Deljanin Ilic1
Juan Carlos Kaski2
1Institute for treatment and
rehabilitation “Niska Banja” Niska Banja
2 St.George's Hospital, London
SAŽETAK
Pregnancy-associated plasma
protein-A (PAPP-A) is high-molecular-weight metalloproteinase originally
identified in the serum of pregnant women. During pregnancy, the concentration
of PAPP-A increases in maternal circulation with gestational age. Depressed
levels, associated with an abnormal placental function, have formed the basis of
the first trimester screening for Down syndrome. The role of PAPP-A in tissue
other than placenta has only recently been explored. Higher PAPP-A
concentrations have been found in patients with acute coronary syndrome (ACS)
when compared to the patients with stable angina and subjects without coronary
artery disease. A very recent study indicates that, even in patients with stable
coronary heart disease, PAPP-A levels are associated with angiographic plaque
complexity and atherosclerotic disease extent.
In addition, elevated PAPP-A concentrations have shown to be
associated with adverse cardiac events in ACS patients and in patients with
chronic stable coronary artery disease (CSA). Noteworthy, the PAPP-A form that
accounts for increase in ACS is non-complexed with the proform of eosinophil
major basic protein (proMBP). However, PAPP-A assays applied in clinical studies
published thus far detect total PAPP-A. Consequently, the clinical value may be
non-optimal when total PAPP-A is measured in patients with coronary artery
disease (CAD).
PAPP-A appears to be a very promising biomarker useful in the
clinical management of CSA patients. However, more prospective studies with
carefully established immunoassays are required to validate its clinical
utility.
Key words: pregnancy-associated plasma protein-A,
coronary artery disease